Deloitte finalises Recom buy
Friday, 18 July, 2008
Global financial services giant Deloitte has completed the acquisition of Recombinant Capital, the San Francisco-based life sciences subscription database and advisory services firm.
The financial terms of the deal have not been disclosed.
In a statement, Deloitte said the new business will be known as Deloitte Recap LLC, or Recap.
The acquisition includes Recombinant Capital's database of 1,500 subscribers, who have access to over 20 years of historical data on publicly available information in the life sciences industry, ranging from alliance formations to intellectual property ownership and clinical trials data.
Deloitte said Recap's customers will include approximately 90 per cent of the top-tier biotech and pharmaceutical companies in the US by market capitalisation. The company also serves as a supplier of data to organisations, including venture capital firms, major law firms, universities and medical centres.
Anti-inflammatory drug may help treat alcohol use disorder
A drug that is already FDA-approved for treating inflammatory conditions may help reduce both...
Osteoarthritis study uncovers new genetic links, drug targets
The genome-wide association study (GWAS) uncovered over 900 genetic associations, more than 500...
How brain cells are affected by Tourette syndrome
US researchers have conducted a cell-by-cell analysis of brain tissue from individuals with...
